Drug Profile
INO 3401
Alternative Names: INO-3401Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals
- Class Influenza A virus H5N1 vaccines; Influenza virus DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype
Most Recent Events
- 01 Feb 2014 Inovio Pharmaceuticals completes a phase I trial for Influenza-A virus H1N1 subtype (prevention, in healthy volunteers) in USA (NCT01405885)
- 31 May 2011 Phase-I clinical trials in Influenza-A virus H5N1 subtype (in healthy volunteers) in USA (Intradermal)